Replies to post #121178 on Anavex Life Sciences Corp (AVXL)

[F1ash]

I'm not a teacher nor do I write these PR's for Anavex.

Anavex apparently caused confusion by including this statement in today's PR.

"The Michael J. Fox Foundation for Parkinson’s Research has awarded Anavex a research grant to develop ANAVEX™ 2-73 for the treatment of Parkinson’s disease to fully fund a preclinical study, "

They might have been better served to have quoted the recent S3 instead?






"In September 2016, the Company presented positive preclinical data for ANAVEX TM 2-73 in Parkinson’s disease, which demonstrated significant improvements on all measures: behavioral, histopathological, and neuroinflammatory endpoints. The study was funded by the Michael J Fox Foundation (“MJFF”)."

http://secfilings.nasdaq.com/filingFrameset.asp?FilingID=12095946&RcvdDate=5/26/2017&CoName=ANAVEX%20LIFE%20SCIENCES%20CORP.&FormType=S-3&View=html

Perhaps it's time to update their boilerplate "About Anavex" PR section?